1200 Summit Avenue
Suite 414
Fort Worth, TX 76102
United States
817 529 2300
https://sanaramedtech.com
Settore/i: Healthcare
Settore: Medical Instruments & Supplies
Impiegati a tempo pieno: 107
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Ronald T. Nixon | Executive Chairman | 100k | N/D | 1956 |
Mr. Zachary B. Fleming | Chief Executive Officer | 547,6k | N/D | 1975 |
Mr. Michael D. McNeil | CFO & Corporate Secretary | 331,1k | N/D | 1965 |
Mr. Jacob A. Waldrop | Chief Operating Officer | N/D | N/D | N/D |
Mr. Bill Fitzgerald | Chief Compliance Officer | N/D | N/D | N/D |
Ms. Tricia Matteson | Vice President of Marketing | N/D | N/D | N/D |
Mr. Tyler Palmer | Chief Corporate Development & Strategy Officer | N/D | N/D | N/D |
Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D. | President of Telehealth Services | 156k | N/D | 1970 |
Dr. Rebecca Erin Mcmahon | President of Research & Development | N/D | N/D | 1985 |
Mr. Seth Yon | President of Commercial | N/D | N/D | N/D |
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
L'ISS Governance QualityScore di Sanara MedTech Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 3; retribuzione: 7.